
The 'biohacking' trend that has tech workers experimenting on themselves
About this episode
In an industry known for pushing the bounds of human innovation, tech elites are now trying to push the bounds of their own bodies. The hot new biohacking trend is injectable peptides — similar to the ones found in GLP-1 medications like Ozempic. But these are not approved by the Food and Drug Administration.
These gray-market peptides, largely from Chinese manufacturers, are being used by tech workers and founders. Not just to lose weight, but to optimize their health and performance in all manner of ways. “Marketplace Tech” host Meghan McCarty Carino speaks with independent journalist Jasmine Sun, who recently wrote about this for the New York Times.
Get every episode summarized
Each time Marketplace Tech publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Marketplace Tech

Raising kids in an AI-driven world
Marketplace Tech

What AI can and can't do for you (for now)
Marketplace Tech

Amid Silicon Valley scramble for AI agent productivity, "token anxiety" takes ho...
Marketplace Tech

Anthropic’s new, powerful allies: Elon Musk and SpaceX
Marketplace Tech